NeuroMetrix Historical Financial Ratios
| NURO Stock | USD 4.25 0.03 0.71% |
NeuroMetrix is lately reporting on over 105 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 41.56 will help investors to properly organize and evaluate NeuroMetrix financial condition quickly.
NeuroMetrix |
About NeuroMetrix Financial Ratios Analysis
NeuroMetrixFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NeuroMetrix investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NeuroMetrix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NeuroMetrix history.
NeuroMetrix Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing NeuroMetrix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on NeuroMetrix sales, a figure that is much harder to manipulate than other NeuroMetrix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is NeuroMetrix dividend as a percentage of NeuroMetrix stock price. NeuroMetrix dividend yield is a measure of NeuroMetrix stock productivity, which can be interpreted as interest rate earned on an NeuroMetrix investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from NeuroMetrix's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NeuroMetrix current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.At this time, NeuroMetrix's Capex To Revenue is very stable compared to the past year. As of the 27th of November 2024, Days Payables Outstanding is likely to grow to 53.59, while Price To Sales Ratio is likely to drop 0.60.
| 2023 | 2024 (projected) | Dividend Yield | 20.92 | 21.96 | Price To Sales Ratio | 0.64 | 0.6 |
NeuroMetrix fundamentals Correlations
Click cells to compare fundamentals
NeuroMetrix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NeuroMetrix fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 4.41 | 12.98 | 12.48 | 1.29 | 0.64 | 0.6 | |
| Ptb Ratio | 16.15 | 18.25 | 4.44 | 0.45 | 0.19 | 0.18 | |
| Days Sales Outstanding | 19.21 | 16.54 | 13.75 | 28.59 | 32.09 | 41.56 | |
| Book Value Per Share | 2.13 | 1.39 | 9.05 | 26.21 | 19.28 | 18.32 | |
| Free Cash Flow Yield | (0.0898) | (0.0216) | (0.0214) | (0.5) | (1.67) | (1.59) | |
| Operating Cash Flow Per Share | (3.05) | (0.55) | (0.81) | (5.93) | (5.84) | (6.13) | |
| Stock Based Compensation To Revenue | 0.0205 | 0.0812 | 0.0846 | 0.0578 | 0.12 | 0.11 | |
| Capex To Depreciation | 0.85 | 0.39 | 1.72 | 0.47 | 3.29 | 3.46 | |
| Pb Ratio | 16.15 | 18.25 | 4.44 | 0.45 | 0.19 | 0.18 | |
| Ev To Sales | 4.17 | 12.33 | 9.78 | 0.81 | 0.38 | 0.36 | |
| Free Cash Flow Per Share | (3.09) | (0.55) | (0.86) | (5.96) | (6.02) | (6.32) | |
| Roic | (4.41) | (0.38) | (0.0942) | (0.2) | (0.35) | (0.34) | |
| Inventory Turnover | 6.04 | 2.02 | 3.3 | 1.55 | 1.25 | 1.19 | |
| Net Income Per Share | (3.07) | (0.53) | (0.86) | (4.9) | (6.27) | (6.58) | |
| Days Of Inventory On Hand | 60.45 | 180.28 | 110.6 | 235.24 | 291.29 | 305.86 | |
| Payables Turnover | 9.68 | 14.96 | 8.21 | 6.81 | 9.07 | 11.72 | |
| Sales General And Administrative To Revenue | 0.33 | 0.3 | 0.64 | 0.48 | 0.53 | 0.84 | |
| Research And Ddevelopement To Revenue | 0.2 | 0.32 | 0.33 | 0.31 | 0.39 | 0.29 | |
| Capex To Revenue | 0.008924 | 0.005185 | 0.016 | 0.002808 | 0.0311 | 0.0327 | |
| Cash Per Share | 2.63 | 1.38 | 8.8 | 23.79 | 17.27 | 16.41 | |
| Pocfratio | (11.29) | (46.32) | (49.68) | (2.01) | (0.62) | (0.59) | |
| Capex To Operating Cash Flow | 0.0502 | (0.0133) | (0.0635) | (0.004383) | (0.0302) | (0.0317) | |
| Pfcf Ratio | (11.14) | (46.32) | (46.71) | (2.0) | (0.6) | (0.57) | |
| Days Payables Outstanding | 37.69 | 24.41 | 44.46 | 53.61 | 40.26 | 53.59 | |
| Roe | (1.44) | (0.38) | (0.095) | (0.19) | (0.32) | (0.34) | |
| Ev To Operating Cash Flow | (10.68) | (44.02) | (38.94) | (1.27) | (0.37) | (0.35) | |
| Pe Ratio | (11.2) | (47.82) | (46.72) | (2.43) | (0.57) | (0.55) | |
| Return On Tangible Assets | (0.53) | (0.25) | (0.0886) | (0.18) | (0.3) | (0.32) | |
| Ev To Free Cash Flow | (10.54) | (44.02) | (36.62) | (1.27) | (0.36) | (0.34) | |
| Earnings Yield | (0.0893) | (0.0209) | (0.0214) | (0.41) | (1.74) | (1.83) | |
| Net Debt To E B I T D A | 0.25 | 2.38 | 10.08 | 0.83 | 0.21 | 0.2 | |
| Current Ratio | 1.58 | 3.1 | 17.71 | 21.79 | 16.81 | 17.65 | |
| Tangible Book Value Per Share | 2.13 | 1.39 | 9.05 | 26.21 | 19.28 | 18.32 |
Pair Trading with NeuroMetrix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeuroMetrix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuroMetrix will appreciate offsetting losses from the drop in the long position's value.Moving against NeuroMetrix Stock
| 0.49 | LH | Laboratory | PairCorr |
| 0.45 | MOH | Molina Healthcare | PairCorr |
| 0.43 | HUM | Humana Inc Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.34 | UNH | UnitedHealth Group Fiscal Year End 10th of January 2025 | PairCorr |
| 0.31 | XAIR | Beyond Air | PairCorr |
The ability to find closely correlated positions to NeuroMetrix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeuroMetrix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeuroMetrix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeuroMetrix to buy it.
The correlation of NeuroMetrix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeuroMetrix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeuroMetrix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeuroMetrix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share 2.157 | Quarterly Revenue Growth (0.51) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.